Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Patient Capital Management 2024 Q3 Investor Letter | Buyside Digest

Back to Fund Profile (Patient Capital Management)

Primary Source Intelligence • Q3 2024 Letter Analysis

Patient Capital Management Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Patient Capital Management. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

QTD+5.8%

Annualized+7.6%

Digest Analysis

Quick Take

"Patient Capital Management delivered solid Q3 returns while warning of quality compounder overvaluation reminiscent of the Nifty Fifty era. The firm added small-cap positions QXO and Dave & Busters, positioning for long-term outperformance in undervalued segments."

Executive Summary

Patient Capital Management's Opportunity Equity Strategy gained 5.8% in Q3 2024, slightly trailing the S&P 500's 5.9% return but maintaining strong longer-term performance with 63% cumulative returns since late 2022 versus 54% for the benchmark. Manager Samantha McLemore emphasizes the importance of embracing underperformers in a market dominated by quality compounder enthusiasm. The strategy added two new small-to-mid cap positions, QXO and Dave & Busters, while exiting JP Morgan due to full valuation. QXO became the largest position after a successful PIPE investment, leveraging proven operator Brad Jacobs' track record. The portfolio trades at a significant discount to the market with 12x forward earnings versus 22x for the S&P 500, while offering better growth prospects. McLemore warns of similarities to the Nifty Fifty period, noting quality compounders trade at 47% premium valuations. The firm maintains conviction in its value-oriented approach, believing current conditions favor patient capital deployment in undervalued segments where market expectations are depressed.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

72%

CautiousHigh

High Conviction (72%)

Manager demonstrates high conviction through concentrated position sizing (QXO became largest position from new holding), specific return targets for Dave & Busters (mid-$80s price target), and clear thesis articulation. Names specific positions with detailed analysis and sizing decisions, though maintains diversified approach across multiple holdings.

Growth Outlook

25%

BearishBullish

Bearish (25%)

Manager acknowledges remaining in a bull market with strong 2-year performance but expresses caution about quality compounder valuations and similarities to Nifty Fifty period. Balanced view with constructive elements tempered by valuation concerns.

Risk Appetite

40%

DefensiveAggressive

Defensive (40%)

Added two new positions during the quarter and maintains conviction in portfolio positioning. Selectively deploying capital in undervalued segments while maintaining diversified exposure across market caps and styles.

Capital Deployment

35%

De-riskingDeploying

Net Neutral (35%)

Added two new positions (QXO and Dave & Busters) while exiting two others (JP Morgan and Everi). Net activity suggests moderate deployment into selective opportunities, particularly in small-to-mid cap space. No cash level changes disclosed but portfolio activity indicates selective capital rotation.

Forward Guidance

30%

CautiousExpansionary

Cautious (30%)

Manager plans to continue assessing opportunities and positioning for maximal compounding. Selective deployment bias toward undervalued areas while exercising discretion in quality compounders. Watching for entry points in depressed segments.

Language Signal

10%

BearishBullish

Bearish (10%)

Language emphasizes opportunities in undervalued segments and long-term compounding potential, but balanced by significant caution about elevated valuations, crowding risks, and potential for significant losses in quality names.

Perceived Risk

75%

Low RiskElevated

Elevated Risk (75%)

Manager extensively discusses risks of quality compounder overvaluation, drawing parallels to Nifty Fifty period when stocks lost half their value. Warns of investor crowding, elevated multiples, and potential for significant losses. Detailed risk analysis with specific historical comparisons and valuation metrics.

Opportunity Density

65%

ScarceAbundant

Abundant (65%)

Manager sees selective opportunities in undervalued segments, particularly small caps and value names where assets have flowed away. Emphasizes greater opportunity in areas with depressed expectations while noting limited appeal in crowded quality compounders. Mixed opportunity set requiring selectivity.

Time Horizon

80%

Short-TermLong-Term

Decade+ (80%)

Strong emphasis on long-term compounding with multi-year thesis for holdings. Dave & Busters analysis extends 3 years forward, QXO positioned for decade-plus growth potential. Manager explicitly discusses patient capital approach and willingness to hold through volatility. Firm name Patient Capital reinforces long-term orientation.